Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.2 mg (equivalent: desmopressin, qty 178 microgram) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; povidone; potato starch - minirin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg/ml (equivalent: desmopressin, qty 0.089 mg/ml) - spray, solution - excipient ingredients: dibasic sodium phosphate dihydrate; citric acid monohydrate; sodium chloride; purified water; benzalkonium chloride - diabetes insipidus:the treatment of adh-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.,nocturnal enuresis: minirin nasal spray is indicated for the symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. minirin nasal spray should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible.,renal concentrating capacity: by intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 100 µg/ml equivalent to 8 9µg/ml desmopressin free base - nasal drops - 100 mcg/ml - active: desmopressin acetate trihydrate 100 µg/ml equivalent to 8 9µg/ml desmopressin free base excipient: chlorobutanol hemihydrate hydrochloric acid purified water sodium chloride - minirin nasal drops solution is indicated for the treatment of central diabetes insipidus and for establishing renal concentration capacity testing.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 4 microgram/ml (equivalent: desmopressin, qty 3.56 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - diabetes insipidus: the treatment of adh sensitive cranial diabetes insipidus, including treatment of post hypophysectomy polydipsia and polyuria.,renal concentrating capacity: by intramuscular administration to adults only, as a diagnostic test to establish renal concentrating capacity.,mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for p

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 240 microgram (equivalent: desmopressin acetate, qty 272 microgram) - wafer - excipient ingredients: mannitol; citric acid; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 120 microgram (equivalent: desmopressin acetate, qty 136 microgram) - wafer - excipient ingredients: citric acid; mannitol; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg (equivalent: desmopressin, qty 89 microgram) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; potato starch; povidone - minirin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - desmopressin as acetate - tablets soluble - desmopressin as acetate 60 mcg - desmopressin - desmopressin - nocturnal enuresis.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - desmopressin as acetate - tablets soluble - desmopressin as acetate 120 mcg - desmopressin - desmopressin - nocturnal enuresis.